Author's response to reviews

Title: Safety and survival effect comparision of adjuvant tamoxifen and toremifene in premenopausal patients with ER/PR positive breast cancer: a retrospective cohort study

Authors:

Fengxi Su Prof (fengxisu@vip.163.com)
Ran Gu Dr (ccaibai@qq.com)
Weijuan Jia M.D. (jaweijuan@yahoo.com.cn)
Yunjie Zeng Dr (zyj81332590@126.com)
Nanyan Rao Prof (raonany@126.com)
Yue Hu Dr (fionahu126@126.com)
Shunrong Li Dr (lison2000@163.com)
Jiannan Wu Dr (king8702@163.com)
Liang Jin Dr (jinl2001@qq.com)
Lijuan Chen (337330348@qq.com)
Erwei Song Prof (songew@mail.sysu.edu.cn)
Meijun Long Dr (meijunlong@yahoo.com.cn)
Kai Chen Dr (ckaichen@126.com)
Qiaozhen Xiao (ccaibai@sina.com)
Mei Wu (wumeixiaopig@163.com)
Lili Chen (ccaibai@163.com)

Version: 10 Date: 16 June 2011

Author's response to reviews: see over
Dear editor:

We submit our manuscript entitled "Safety and survival effect comparison of adjuvant tamoxifen and toremifene in premenopausal patients with ER/PR positive breast cancer: a retrospective cohort study" to BMC cancer for publication. We aimed to establish whether toremifene should be part of endocrine therapy for premenopausal patients with ER/PR positive breast cancer besides tamoxifen.

The expert panel of the 2009 St. Gallen Conference accepted either tamoxifen or tamoxifen plus ovarian suppression as standard endocrine therapy for premenopausal patients. Unfortunately, long-term safety data for tamoxifen have raised concerns over many widely recognized adverse event associated with this therapy: the increased risk of secondary endometrial cancers, increases in pulmonary embolism, deep vein thrombosis, and stroke. Toremifene is a synthetic analogue of tamoxifen and was developed to improve its risk–benefit profile. However, few studies have investigated the therapeutic role of toremifene as adjuvant endocrine therapy for premenopausal breast cancer patients. So we aimed to study whether toremifene is a valid and safe alternative to tamoxifen in premenopausal women with endocrine-responsive breast cancer.

All authors have seen the manuscript and approved to submit to your journal.

Thank you very much for your attention and consideration.

With kind personal regards,

Sincerely yours,

Fengxi Su,
Erwei Song